The effect of smoking and age on the response to first-line therapy of hidradenitis suppurativa: An institutional retrospective cohort study - 18/04/17
Abstract |
Background |
Treatment for hidradenitis suppurativa is often empiric and inadequate, and determining which patients will respond is difficult.
Objective |
We sought to determine which patient factors are associated with a positive response to first-line medical therapy.
Methods |
A single-center retrospective cohort study of all patients with hidradenitis suppurativa seen between January 1, 1992, and October 1, 2014, was conducted. Response to first-line medical therapy (oral/topical antibiotics, intralesional corticosteroids, and topical washes) was examined at follow-up within 6 months of initiating therapy. A multivariate binary logistic regression model was built examining response to treatment and the interplay of patient factors and treatment initiated.
Results |
In all, 198 patients were included in the final model. Nonsmokers (odds ratio 2.634, 95% confidence interval 1.301-5.332, P = .007) and older individuals (odds ratio 1.046 for each additional year, 95% confidence interval 1.020-1.072, P < .001) were more likely to have improvement at follow-up. In addition, current smokers differed significantly from nonsmokers in several regards.
Limitations |
The retrospective nature of this study is a limitation, as is relying on classification of disease severity from physical examination findings in some patients.
Conclusions |
The results of this study suggest that clinicians may be able to more accurately predict which patients with hidradenitis suppurativa will respond to first-line medical therapy, and which patients may require therapy escalation.
Le texte complet de cet article est disponible en PDF.Key words : acne inversa, first-line treatment, hidradenitis suppurativa, increased age, medical therapy, patient response, smoking
Abbreviations used : CI, EMR, HS, OR
Plan
This publication was supported by the Washington University Institute of Clinical and Translational Sciences grant TL1 TR000449 from the National Center for Advancing Translational Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. |
|
Disclosure: Dr Anadkat has received honoraria as a speaker and/or consultant from AstraZeneca, Bristol-Myers Squibb, Eisai, ImClone, and Therakos. He has also served as an investigator for Hana Biosciences and Xoma. Dr Denny has served as a consultant for Epharmix. |
Vol 76 - N° 1
P. 54-59 - janvier 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?